Knockdown of CXCR4 sensitized the tumor cells to trastuzumab in two-line co-culture (Fig. 2D), suggesting CXCR4 plays a role in the function of trastuzumab by interrupting HER2 oncogenic signals. The gene discussed is ERBB2; the disease is neoplasm.